TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
Year: 2018
Type: review
Abstract: Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of TP53 and/or deletions in chromosome 17p [del(17p)], resulting in loss of one TP53 allele. These aberrations are associated with markedly decreased survival and predict impaired response to chemoimmunotherapy thus being among the strongest predictive markers guiding treatment decisions in chronic lymphocytic leukemia. Clinical trials demonstrate the importance of accurately testing for TP53 aberrations [both del(17p) and TP53 mutations] before each line of treatment to allow for appropriate treatment decisions that can optimize patients’ outcomes. The current report reviews the diagnostic methods to detect TP53 disruption better, the role of TP53 aberrations in treatment decisions and current therapies available for patients with chronic lymphocytic leukemia carrying these abnormalities. The standardization in sequencing technologies for accurate identification of TP53 mutations and the importance of continued evaluation of TP53 aberrations throughout initial and subsequent lines of therapy remain unmet clinical needs as new therapeutic alternatives become available.
Source: Haematologica
Institutions: Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Université Sorbonne Paris Nord, Assistance Publique – Hôpitaux de Paris, Hôpital Avicenne, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Medical University of Vienna, Masaryk University, Central European Institute of Technology – Masaryk University, Karolinska Institutet, University of Oxford, Universität Ulm, Universitätsklinikum des Saarlandes
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Funders: Gilead Sciences, National Institute for Health and Care Research, Deutsche Forschungsgemeinschaft, Ministerstvo Školství, Mládeže a Tělovýchovy, Central European Institute of Technology, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, NIHR Oxford Biomedical Research Centre
OpenAlex ID: W2901396567
